[HTML][HTML] Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer …
X Pivot, J Gligorov, V Müller, G Curigliano, A Knoop… - Annals of oncology, 2014 - Elsevier
Background Patients with HER2-positive early breast cancer (EBC) preferred subcutaneous
(sc) trastuzumab, delivered via single-use injection device (SID), over the intravenous (iv) …
(sc) trastuzumab, delivered via single-use injection device (SID), over the intravenous (iv) …
[PDF][PDF] PatientsL preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer …
X Pivot, J Gligorov, V Müller, G Curigliano, A Knoop… - Am J Pathol, 2009 - researchgate.net
original articles Page 1 14. Thor AD, Edgerton SM, Jones FE. Subcellular localization of the
HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer …
HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer …
[PDF][PDF] PatientsL preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer …
X Pivot, J Gligorov, V Müller, G Curigliano, A Knoop… - Am J Pathol, 2009 - core.ac.uk
original articles Page 1 14. Thor AD, Edgerton SM, Jones FE. Subcellular localization of the
HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer …
HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer …
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final …
X Pivot, J Gligorov, V Müller… - Annals of oncology …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Patients with HER2-positive early breast cancer (EBC) preferred subcutaneous
(sc) trastuzumab, delivered via single-use injection device (SID), over the intravenous (iv) …
(sc) trastuzumab, delivered via single-use injection device (SID), over the intravenous (iv) …
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final …
X Pivot, J Gligorov, V Müller, G Curigliano… - Annals of Oncology …, 2014 - europepmc.org
Background Patients with HER2-positive early breast cancer (EBC) preferred subcutaneous
(sc) trastuzumab, delivered via single-use injection device (SID), over the intravenous (iv) …
(sc) trastuzumab, delivered via single-use injection device (SID), over the intravenous (iv) …
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final …
X Pivot, J Gligorov, V Müller, G Curigliano, A Knoop… - sussex.figshare.com
BACKGROUND: Patients with HER2-positive early breast cancer (EBC) preferred
subcutaneous (SC) trastuzumab, delivered via single-use injection device (SID), over the …
subcutaneous (SC) trastuzumab, delivered via single-use injection device (SID), over the …
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final …
X Pivot, J Gligorov, V Müller, G Curigliano… - ANNALS OF …, 2014 - air.unimi.it
BACKGROUND: Patients with HER2-positive early breast cancer (EBC) preferred
subcutaneous (sc) trastuzumab, delivered via single-use injection device (SID), over the …
subcutaneous (sc) trastuzumab, delivered via single-use injection device (SID), over the …
[HTML][HTML] Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer …
X Pivot, J Gligorov, V Müller, G Curigliano, A Knoop… - Annals of …, 2014 - doc.rero.ch
PrefHer revealed compelling and consistent patient preference for subcutaneous (sc)
trastuzumab, regardless of delivery by single-use injection device or hand-held syringe. sc …
trastuzumab, regardless of delivery by single-use injection device or hand-held syringe. sc …
[引用][C] Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer …
X PIVOT, J GLIGOROV, V MÜLLER… - Annals of …, 2014 - pascal-francis.inist.fr
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the
adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the …
adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the …
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final …
X Pivot, J Gligorov, V Müller, G Curigliano… - Annals of …, 2014 - annalsofoncology.org
Background Patients with HER2-positive early breast cancer (EBC) preferred subcutaneous
(sc) trastuzumab, delivered via single-use injection device (SID), over the intravenous (iv) …
(sc) trastuzumab, delivered via single-use injection device (SID), over the intravenous (iv) …